» Authors » Alessia Ciancio

Alessia Ciancio

Explore the profile of Alessia Ciancio including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 101
Citations 924
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Rinaldi L, Vigano M, Ciancio A, Caturano A, Messina V, Niro G, et al.
Viruses . 2025 Feb; 17(2). PMID: 40007006
Introduction: Hepatitis D virus (HDV) infection remains a significant global health challenge due to its severity and high risk of progression to cirrhosis and hepatocellular carcinoma (HCC). Bulevirtide, a novel...
2.
Degasperi E, Anolli M, Jachs M, Reiberger T, de Ledinghen V, Metivier S, et al.
J Hepatol . 2025 Jan; PMID: 39793613
Background & Aims: Bulevirtide (BLV) 2 mg/day is EMA approved for the treatment of compensated chronic HDV infection; however, real-world data in large cohorts of patients with cirrhosis are lacking....
3.
Smirne C, Crobu M, Landi I, Vercellino N, Apostolo D, Pinato D, et al.
Viruses . 2025 Jan; 16(12. PMID: 39772206
Hepatitis C virus (HCV) infection is a significant risk factor for liver cirrhosis and hepatocellular carcinoma (HCC). Traditionally, the primary prevention strategy for HCV-associated HCC has focused on removing infection...
4.
Caviglia G, DAmbrosio R, Colombatto P, Ciancio A
Aliment Pharmacol Ther . 2024 Dec; 61(3):585-586. PMID: 39723756
No abstract available.
5.
Caviglia G, Fariselli P, DAmbrosio R, Colombatto P, Degasperi E, Ricco G, et al.
Aliment Pharmacol Ther . 2024 Nov; 61(3):538-549. PMID: 39569574
Background And Aims: Patients with hepatitis C virus (HCV)-related cirrhosis with sustained virological response (SVR) to direct-acting antivirals (DAA) remain at risk of developing hepatocellular carcinoma (HCC). Recently, serum protein...
6.
Rosato V, Nevola R, Dallio M, Di Micco P, Spinetti A, Zeneli L, et al.
J Clin Med . 2024 Oct; 13(19). PMID: 39407867
Direct oral anticoagulants (DOACs) are recommended for the management of thrombosis prophylaxis, especially in patients with atrial fibrillation. As substrates of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein, they are implicated...
7.
Caviglia G, Casalone E, Olivero A, Birolo G, Ciancio A, Matullo G, et al.
J Viral Hepat . 2024 Aug; 31(11):771-774. PMID: 39129189
Micro-RNAs (miRNAs) are involved in the modulation of viral replication and host immune antiviral response. Using next-generation sequencing, we investigated the miRNome profile of circulating extracellular vesicles in 20 patients...
8.
Kondili L, Brancaccio G, Tosti M, Coco B, Quaranta M, Messina V, et al.
Int J Infect Dis . 2024 May; 146:107115. PMID: 38801968
Background And Aims: We aimed to characterize the epidemiologic and comorbidities profiles of patients with chronic Hepatitis D (CHD) followed in clinical practice in Italy and explored their interferon (IFN)...
9.
Concerto C, Signorelli M, Chiarenza C, Ciancio A, Di Francesco A, Mineo L, et al.
J Integr Neurosci . 2024 Jan; 22(6):164. PMID: 38176943
Background: Gambling Disorder (GD) is a behavioral addiction listed within the diagnostic category of substance-related and addictive disorders. Recently, transcranial magnetic stimulation (TMS), which non-invasively stimulates the brain and has...
10.
Kondili L, Zanetto A, Quaranta M, Ferrigno L, Panetta V, Calvaruso V, et al.
United European Gastroenterol J . 2023 Nov; 12(3):352-363. PMID: 38032175
Background & Aims: Sustained virological response (SVR) by direct-acting antivirals (DAAs) may reverse the hypercoagulable state of HCV cirrhosis and the portal vein thrombosis (PVT) risk. We evaluated the incidence...